CWA Asset Management Group LLC Has $1.34 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

CWA Asset Management Group LLC raised its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 33.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,281 shares of the biotechnology company's stock after purchasing an additional 9,080 shares during the quarter. CWA Asset Management Group LLC's holdings in Exelixis were worth $1,339,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Coppell Advisory Solutions LLC bought a new position in shares of Exelixis in the fourth quarter valued at $25,000. Colonial Trust Co SC lifted its stake in Exelixis by 616.9% in the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 765 shares during the last quarter. Principal Securities Inc. lifted its stake in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 373 shares during the last quarter. Kestra Investment Management LLC bought a new position in shares of Exelixis in the 4th quarter valued at about $39,000. Finally, Crowley Wealth Management Inc. acquired a new position in shares of Exelixis during the 4th quarter worth about $50,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on EXEL. Bank of America raised their target price on shares of Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a research note on Thursday, June 5th. Wall Street Zen cut Exelixis from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 15th. Morgan Stanley reiterated an "overweight" rating and set a $47.00 target price (up from $40.00) on shares of Exelixis in a research note on Wednesday, May 14th. Royal Bank Of Canada restated an "outperform" rating and issued a $40.00 price target on shares of Exelixis in a research note on Wednesday, May 14th. Finally, UBS Group reaffirmed an "underperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $39.76.

Exelixis Stock Down 1.5%

Shares of Exelixis stock opened at $40.74 on Friday. The stock has a market capitalization of $11.11 billion, a price-to-earnings ratio of 18.52, a price-to-earnings-growth ratio of 0.83 and a beta of 0.28. Exelixis, Inc. has a twelve month low of $21.36 and a twelve month high of $48.85. The company has a 50-day simple moving average of $40.20 and a two-hundred day simple moving average of $37.01.

Insider Transactions at Exelixis

In related news, Director George Poste sold 20,634 shares of the business's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $45.99, for a total value of $948,957.66. Following the completion of the transaction, the director now owns 169,020 shares of the company's stock, valued at $7,773,229.80. The trade was a 10.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Dana Aftab sold 1,508 shares of the company's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $39.00, for a total transaction of $58,812.00. Following the sale, the executive vice president now directly owns 693,181 shares of the company's stock, valued at $27,034,059. This represents a 0.22% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 458,113 shares of company stock valued at $21,024,817. 2.82% of the stock is currently owned by company insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.